Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B

Yao, Mingjie; Wang, Leijie; You, Hong; Wang, Jianwen; Liao, Huailin; Yang, Di; Liu, Shuhong; Xu, Qiang; Chen, Xiangmei; Jia, Jidong; Zhao, Jiyun; Lu, Fengmin

doi:10.1016/j.cca.2019.02.019

Cited by 23 publications

(24 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study, we found that elevated serum GP73 levels were a reliable marker of liver fibrosis and cirrhosis 9. Elevated serum GP73 levels were also found to be useful in assessing liver inflammation in chronic viral hepatitis B 10. Also, Lu and Zhang11 confirmed the usefulness of GP73 levels in NAFLD-related cirrhosis.…”

Section: Introductionmentioning

confidence: 72%

Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels

Zheng

Liu

Pan

et al. 2020

BMJ Open Diab Res Care

Self Cite

View full text Add to dashboard Cite

Background and aimImaging-confirmed non-alcoholic fatty liver disease (NAFLD) with normal alanine aminotransferase (nALT) levels is infrequently the subject for further evaluation. Early diagnosis of non-alcoholic steatohepatitis (NASH) is needed to prevent disease progression. Thus, we tested the clinical utility of serum Golgi protein 73 (GP73) levels and developed a new non-invasive score to diagnose NASH in patients with biopsy-confirmed NAFLD and persistent nALT levels.MethodsSerum GP73 and cytokeratin-18 M30 fragments (CK18-M30) levels were measured in 345 patients with biopsy-proven NAFLD. We developed a new score, named G-NASH model (by incorporating serum GP73), and combined it with serum CK18-M30 measurement in a sequential non-invasive approach to accurately identify NASH among patients with NAFLD and persistent nALT levels.Results105 (30.4%) patients had persistent nALT, 53 of whom had histologically confirmed NASH. Both serum GP73 and CK18-M30 levels alone had poor diagnostic accuracy in identifying NASH (55.2% and 51.6%, respectively) in these patients. Conversely, G-NASH model performed better than other established non-invasive scoring systems, and by using our proposed sequential non-invasive approach 82.9% of patients with NASH were correctly identified.ConclusionsNASH is highly prevalent in patients with NAFLD with persistent nALT levels. The G-NASH model accurately identifies NASH in this patient group.

show abstract

Section: Introductionmentioning

confidence: 72%

Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels

Zheng

Liu

Pan

et al. 2020

BMJ Open Diab Res Care

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast, data from others and our laboratory proved that serum GP73 is indeed a surrogate biomarker for liver fibrosis and cirrhosis [26][27][28][29][30]. More recently, studies have shown that GP73 can reflect hepatic inflammatory activity in patients infected with chronic hepatitis B [31,32]. It is well known that the distribution and number of infiltrated inflammatory cells reflect the severity of liver necroinflammation in liver biopsy.…”

Section: Introductionmentioning

confidence: 72%

Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Aims. Persistent hepatic necroinflammatory damage almost always results in fibrosis/cirrhosis or even hepatocellular carcinoma. Therefore, the presence of active necroinflammation in the liver suggests that nonalcoholic fatty liver disease (NAFLD) patients are in urgent need of treatment. Unfortunately, alanine transaminase (ALT), a routine indicator of liver inflammatory damage, showed a poor performance in nonalcoholic steatohepatitis (NASH) patients. Thus, it will be valuable to find an alternative indicator to identify patients with hepatic necroinflammatory damage. In this study, we evaluated the diagnostic value of serum Golgi protein 73 (GP73) for hepatic necroinflammatory damage in patients with NASH. Methods. The clinical data of 201 patients with NASH diagnosed by liver biopsy according to the Brunt staging system were collected retrospectively. The in situ expression of GP73 protein was measured by immunohistochemistry. The receiver operating characteristic (ROC) curve was used to calculate the area under the ROC curve (AUROC) of serum GP73 for diagnosing hepatic necroinflammatory damage. Results. The serum GP73 levels of NASH patients increased with the aggravation of liver necroinflammation. The median levels significantly increased from 49.98 ng/ml (31.49, 75.05) for G0-1 to 76.61 ng/ml (48.68, 110.03) for G2 and to 116.44 ng/ml (103.41, 162.17) for G3 patients (G0-1 vs. G2, P<0.0001; G2 vs. G3, P=0.0228). In consistent, the gradual increase of GP73 protein expression in situ was also observed in liver tissue, in parallel with the increasing severity of necroinflammatory activity. Therefore, serum GP73 correlated well with the intensity of protein expression in liver tissue. The AUROCs of serum GP73 for G2 and G3 inflammatory activity were 0.742 (0.676 to 0.801) and 0.891 (0.840 to 0.931), respectively. Conclusions. GP73 is a valuable alternative serum marker reflecting the severity of hepatic necroinflammation in NASH patients.

show abstract

“…As a serological marker, GP73 has always been controversial. Some reports pointed out that GP73 should be an indicator of liver inflammation and fibrosis instead of a tumor marker 24–27 . Some research results showed that the expression of serum GP73 was significantly higher in the HCC patients compared with the liver fibrosis and cirrhosis patients 28,29 .…”

Section: Discussionmentioning

confidence: 99%

“…Some reports pointed out that GP73 should be an indicator of liver inflammation and fibrosis instead of a tumor marker. [24][25][26][27] Some research results showed that the expression of serum GP73 was significantly higher in the HCC patients compared with the liver fibrosis and cirrhosis patients. 28,29 However, there are few reports on the prognostic value of GP73 in HCC patients.…”

Section: Lots Of Attentions Have Been Paid To the Prognostic Biomarkers Formentioning

confidence: 99%

The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real‐world data

Liu

Wen

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background and aims Hepatocellular carcinoma (HCC) is one of the most common malignancy with poor prognosis, and the mortality rate remains high. More than 70% of HCC patients have recurrence within 5 years after treatment. The purpose of this study is to evaluate the prognostic values of serum markers with retrospective data. Methods We applied real‐world data (RWD) to analyze the prognostic values of six serum markers for HCC patients after treatment, including α‐fetoprotein (AFP), α‐fetoprotein‐L3 (AFP‐L3), Golgi protein73 (GP73), alanine aminotransferase (ALT), albumin (ALB), and total bilirubin (TBil). A total of 268 cases were enrolled to analyze recurrence‐free survival (RFS), and 104 cases were used to analyze overall survival (OS). Results Our results demonstrated that patients with higher AFP and AFP‐L3 had shorter RFS (p = 0.016 and 0.004), while higher GP73, ALT, and TBil experienced longer RFS (p = 0.000, 0.020, and 0.019). Patients with high‐level GP73, ALT, TBil, and low‐level ALB had significantly higher mortality rate (p=0.035, 0.008, 0.010, and 0.005). Multivariate analysis revealed that GP73 (HR = 1.548, p = 0.001) and ALT (HR = 1.316, p = 0.046) were identified as independent prognostic factors for RFS, ALB (HR = 0.127, p = 0.007), and ALT (HR = 0.237, p = 0.01) were identified as independent prognostic factors for OS. Subgroups analysis showed that GP73 had better prognostic values than other serum markers in early‐stage HCC (p = 0.023). Conclusions Our study demonstrates that AFP, AFP‐L3, and GP73 can be used as prognostic indicators for predicting the recurrence of HCC, while liver function tests have better survival prediction values. GP73 can act as a promising prognostic marker for early‐stage HCC.

show abstract

Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B

Cited by 23 publications

References 22 publications

Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels

Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels

Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis

The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real‐world data

Contact Info

Product

Resources

About